


## Affron® supports sleep quality and restorative sleep<sup>6\*</sup>

Affron® intake for 28 days was associated with **greater improvements in:**

- **Significant reduction of 25%** of the **Sleeplessness Severity Index Score**, score<sup>6\*</sup>.
- **Significant increase of 20%** of the **Restorative Sleep Questionnaire (RSQ) score**, related to feeling more energized after awakening (p≤0.05)<sup>6\*</sup>.
- **Significant improvement** in alertness upon awakening (PS-Derry score) (p≤0.05)<sup>6\*</sup>.

**Satisfaction ratings indicated that 96% of participants in the affron® group were satisfied with their tablet intake<sup>6\*</sup>.**

Sleeplessness Severity Index Score



Restorative Sleep Questionnaire Score (RSQ)




Figure 6: Changes in Sleeplessness Severity Index Score and Restorative Sleep Questionnaire.

### Botanical info

Botanical name: *Crocus sativus* L.  
Family: *Iridaceae*.  
Common name: Saffron.  
Part of the plant: Stigma.

### Recommended daily dose

14 mg x2.

### Other info

Shelf life: Three years\*.  
Non-GMO. Non-Irradiated.  
MOQ: 1 Kg.  
Water-soluble.  
Multiple applications. Accurate for food matrices.



\*When stored at room temperature, sheltered from light and moisture.

### Contact us

**GENCOR PACIFIC**  
19700 Fairchild Road, Suite 330, Irvine,  
California 92612, USA.  
Phone: +1 949-502-5760  
Fax: +1 732-875-0306

[contact@gencorpacific.com](mailto:contact@gencorpacific.com)  
[www.gencorpacific.com](http://www.gencorpacific.com)

### PHARMACTIVE BIOTECH PRODUCTS S.L.U.

HEADQUARTERS AND MANUFACTURING PLANT  
Ave. Del Dr. Severo Ochoa, 37, Local 4J.  
28108 Alcobendas, Madrid (Spain).  
+34 91 112 38 48

### QC AND R&D LABORATORIES

Calle Faraday, 7, 28049 Madrid (Spain).  
+34 91 112 38 48

[info@pharmactive.eu](mailto:info@pharmactive.eu)  
[www.pharmactive.eu](http://www.pharmactive.eu)

PHARMACTIVE  
BIOTECH PRODUCTS  
*a natural difference*

(\*) These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

The information contained herein is intended for marketing purposes only and for business to business professionals only. Not to be distributed as such to consumers, patients or sanitary professionals. At Pharmactive Biotech Products, S.L.U. we make every effort to keep all promotional material updated but do not guarantee the accuracy or completeness of the information provided herein. We disclaim any liability for use of this publication and reserve the right to change the content of this publication at any time without notice. The statements have not been approved by The European Commission or The Food and Drug Administration. All access and use of the information contained herein are at the user's own risk.

© 2021 Pharmactive Biotech Products, S.L.U. All rights reserved.

AFUS1021EN



**MAINTAIN A POSITIVE MOOD,  
IMPROVE OCCASIONAL STRESS  
AND SLEEPLESSNESS<sup>1-8\*</sup>**

*affron*®

Contributes to  
relieve the menopause  
symptoms<sup>7\*</sup>

PHARMACTIVE  
BIOTECH PRODUCTS



Features

- 100% Spanish saffron (*Crocus sativus* L.). DNA certified.
- Standardized to ≥3.5% Lepticrosalides® by HPLC-DAD.
- Well-tolerated: No side effects have been reported in +500 participants<sup>1-8\*</sup>.
- High stability.
- 100% vertically integrated.
- Halal and Kosher certified.

+600

1 million people worldwide benefit from affron® to maintain a positive mood and mental balance every day\*

BEST NATURAL ALTERNATIVE TO

Mental balance<sup>1-8\*</sup>

Supportive for menopausal women<sup>7\*</sup>

Helps promote restorative sleep<sup>3,6,8\*</sup>

Bioactive compounds: Lepticrosalides®

Affron® is standardized to ≥3.5% **Lepticrosalides®**, a complex of bioactive compounds responsible for the beneficial and organoleptic properties of **affron®**. They have shown to improve mood in healthy consumers with occasional stress, low mood and sleeplessness<sup>1-8\*</sup>.

They are analysed by the high-reliable technique: HPLC-DAD, which is more precise than the traditional ISO3632 (2003), and which distinguishes between molecular isomers and enables detection of adulteration.

Affron® improves mental outlook<sup>2\*</sup>

In a randomized, double-blind, placebo-controlled study **affron®** intake for 4 weeks, showed signs of improved mood and alleviated stress or tension related anxieties and associated fatigue<sup>2\*</sup>. **Affron®** intake was well tolerated and no associated side effects were noted<sup>2\*</sup>.




Figure 1: POMS "Profile of Mood States".

Differentiated value

- International Patent US2019099464A1.
- 8 clinical studies<sup>1-8</sup>.
- Most clinically backed saffron ingredient worldwide\*.
- Most awared saffron ingredient worldwide\*.
- Unique dose-response study in 128 healthy adults<sup>2\*</sup>.
- 1<sup>st</sup> saffron extract clinically studied in adolescents<sup>4\*</sup>.
- Proven bioavailability (pharmacokinetics study)<sup>9\*</sup>.
- Rapid absorption in 1 hour<sup>9\*</sup>.
- Lowest dosage: 14mg x2/day .
- Made in Spain. Own fields and extraction plant.
- Patented *AFF® ON COOL-Tech* extraction technology, which uniquely concentrates and preserves the actives in a natural way.

Clinically proven to support occasional sleeplessness<sup>8\*</sup>

A new, randomized, double-blind, placebo-controlled study provided **further confirmation of the sleep-enhancing effects of 28 days of affron®** supplementation at 14 mg, 1 hour before bedtime, facilitating consumer's adherence<sup>8\*</sup>.

By the very first time, a single dose of **affron®** 1 hour before sleep revealed new possible mechanism of action influencing sleep hormones<sup>8\*</sup>.




Figure 3: Changes in sleep quality ratings from baseline to week 4.

Affron® supports menopause symptoms<sup>7\*</sup>


In a randomized, double-blind, placebo-controlled study (N=128) **affron®** intake of **28mg/day** for 12 weeks, significantly **improved the psychological aspects** of the Greene Climacteric Scale (GCS), characterized by:

- **33%** reduction in occasional anxiety symptoms<sup>7\*</sup>.
- **32%** reduction in low mood and negative thoughts<sup>7\*</sup>.



Unlock your potential with affron®


Main mecanims of action



AFF® ON Cool-Tech

It is a **patented, low-temperature production process** that creates **highly concentrated affron®** with long-lasting actives's stability. This technique allows us to get superior saffron Quality with **less industrial processing, less energy use and zero chemicals**.

AFF® ON COOL-Tech



Green technology for a Green label

The exclusive **AFF® ON Cool-Tech** process offers a significant advancement in our sustainability efforts as the process **uses less energy and this significantly reduces our carbon footprint**.

Trusted saffron source

We cultivate saffron in our **own fields** in the exceptional Spanish Castilla-La-Mancha region, where *Crocus sativus* L. has been grown and nurtured for centuries. We collaborate with selected saffron farmers, whose craft has been part of their **cultural heritage for centuries**. The art of saffron harvesting requires **manual picking of choice stigmas** during a brief daily window of time.

The **drying of the fresh stigmas is made on-site**, right after the harvesting to ensure maximum actives stability.

References

(1) Lopresti AL, et al. *J Affect Disord*. 2017. 207: 188-196. (2) Kell G., et al. *Complement Ther Med*. 2017 Aug; 33:58-64. (3) Nishide A., et al. *Jpn Pharmacol Ther*. 2018; vol. 46: 8. (4) Lopresti AL., et al. *J Affect Disord*. 2018 May; 232:349-357. (5) Lopresti A., et al. *Journal of Psychopharmacology*. 2019. (6) Lopresti AL., et al. *J Clin Sleep Med*. 2020 Feb14;10.5664/jcsm.8376. (7) Lopresti AL., et al. *Journal of Menopausal Medicine*. 2021;27:1-13. (8) Lopresti AL, et al. *Sleep Medicine*. 2021 Aug;86:7-18. (9) Paula Almodóvar, et al. *Hindawi, Evidence-Based Complementary and Alternative Medicine Volume 2020*. (10) Hosseinzadeh H., et al. *Phytother Res*. 2009 Jun; 23(6):768-74. (11) Georgiadou G., et al. *Neurosci Lett*. 2012 Oct; 18;528(1):27-30. (12) Mehri S., et al. *Iran J Basic Med Sci*. 2015 Sep; 18(9): 902-908. (13) Oruc S., et al. *Life Sci*. 2016 Jun; 1;154:79-86. (14) Ghasemi T., et al. *Drug Res (Stuttg)*. 65: 337-343. (15) Gao K, et al. *Exp Ther Med*. 18: 3775-3782. (16) Poma A, et al. 2012. *Antiinflamm Antiallergy Agents Med Chem*. 11: 37-51.